Gilead Sciences, Inc. (GILD) Financial Statements
Gilead Sciences, Inc. (GILD) reported trailing twelve-month revenue of $30.5B (up 5.5% year on year) and net income of -$3.2B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $12.9B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GILDGilead Sciences, Inc.Follow GILD — free
—
Price chart with a free account
- Market cap
- 193.5B
- P/E TTM
- —
- Dividend yield
- 2.1%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2009 Dec 09 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.01 | 11.20 | 24.89 | 32.64 | 30.39 | 26.11 | 22.13 | 22.45 | 24.69 | 27.31 | 27.28 | 27.12 | 28.75 | 29.44 | 30.46 | |
| Gross profit | 5.42 | 8.34 | 21.10 | 28.63 | 26.13 | 21.74 | 17.27 | 17.77 | 20.12 | 20.70 | 21.62 | 20.62 | 22.50 | 23.21 | 24.24 | |
| Research & development | 0.94 | 2.12 | 2.85 | 3.01 | 5.10 | 3.73 | 5.02 | 9.11 | 4.93 | 4.60 | 4.98 | 5.72 | 5.91 | 5.80 | 6.07 | |
| Operating income | 3.53 | 4.52 | 15.27 | 22.19 | 17.63 | 14.12 | 8.20 | 4.29 | 4.07 | 9.92 | 7.33 | 7.61 | 1.66 | 10.02 | -2.50 | |
| Pre-tax income | 3.50 | 4.21 | 14.86 | 21.66 | 17.10 | 13.53 | 7.80 | 5.16 | 1.67 | 8.28 | 5.81 | 6.86 | 0.69 | 9.80 | -1.96 | |
| Income tax | 0.88 | 1.15 | 2.80 | 3.55 | 3.61 | 8.89 | 2.34 | -0.20 | 1.58 | 2.08 | 1.25 | 1.25 | 0.21 | 1.29 | 1.29 | |
| Net income | 2.64 | 3.08 | 12.10 | 18.11 | 13.50 | 4.63 | 5.46 | 5.39 | 0.12 | 6.23 | 4.59 | 5.67 | 0.48 | 8.51 | -3.24 | |
| Diluted EPS ($) | 2.82 | 1.81 | 7.35 | 11.91 | 9.94 | 3.51 | 4.17 | 4.22 | 0.10 | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 | -2.67 | |
| Diluted shares (bn) | 0.934 | 1.695 | 1.647 | 1.521 | 1.358 | 1.319 | 1.308 | 1.277 | 1.263 | 1.262 | 1.262 | 1.258 | 1.255 | 1.255 | — |
USD billions · SEC XBRL
Gilead Sciences, Inc. — questions
- What is Gilead Sciences, Inc.'s revenue?
- $30.5B over the twelve months to 2026-06-30, up 5.5% year on year, from its 10-Q and 10-K filings.
- What is Gilead Sciences, Inc.'s net income?
- -$3.2B over the twelve months to 2026-06-30.
- What is Gilead Sciences, Inc.'s free cash flow?
- $12.9B over the twelve months to 2026-06-30.
- What are Gilead Sciences, Inc.'s diluted earnings per share?
- $-2.67 over the twelve months to 2026-06-30.
Every figure on this page comes from Gilead Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.